ALK and lung adenocarcinoma: In addition, 14 lung adenocarcinoma patients positive for EGFR mutation displayed a significantly higher n-Dodecane VOC peak than for 14 lung adenocarcinoma patients negative for the EGFR mutation without 4 patients positive for ALK fusion (p<0.01), with a sensitivity of 85.7% and a specificity of 78.6% (Figs. 4 and 5).